<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363077</url>
  </required_header>
  <id_info>
    <org_study_id>107975</org_study_id>
    <nct_id>NCT00363077</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate</brief_title>
  <official_title>A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and the safety of the candidate
      vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia. The seropositivity cut-off assay was 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Day 0 and Day 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Day 21</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>The geometric mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>The geometric mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were considered to be related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 30-day (Days 0-29) post vaccination period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented everyday activities. Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (from Day 0 to Day 29)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE considered by the investigator to have a causal relationship to study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1247446A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK1247446A Group</intervention_name>
    <description>Low dose influenza vaccine adjuvanted with AS03 compared</description>
    <arm_group_label>GSK1247446A Group</arm_group_label>
    <other_name>Low dose adjuvanted influenza vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and wil comply with the
             requirements of the protocol should be enrolled in the study.

          -  A male or female 60 years or older at the time of the first vaccination.

          -  Free of obvious health problems

        Exclusion Criteria:

          -  Use of non-registered products

          -  Administration of immune-modifying drugs.

          -  Administration of vaccine 30 days before enrolment in study.

          -  Immunosuppressive or immunodeficient condition.

          -  Hypersensitivity to a previous dose of influenza vaccine

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality.

          -  History of confirmed influenza infection within the last 12 Months.

          -  Acute disease at the time of enrolment/vaccination.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>March 21, 2013</results_first_submitted>
  <results_first_submitted_qc>March 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2013</results_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Prophylaxis Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107975</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107975</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107975</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107975</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107975</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="4.22"/>
                    <measurement group_id="B2" value="64.5" spread="4.18"/>
                    <measurement group_id="B3" value="64.4" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia. The seropositivity cut-off assay was 1:10.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia. The seropositivity cut-off assay was 1:10.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="35.9" upper_limit="57.1"/>
                    <measurement group_id="O2" value="81.1" lower_limit="61.5" upper_limit="106.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" lower_limit="91.2" upper_limit="148.5"/>
                    <measurement group_id="O2" value="170.9" lower_limit="132.7" upper_limit="220.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="20.7" upper_limit="40.1"/>
                    <measurement group_id="O2" value="41.3" lower_limit="29.1" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.9" lower_limit="188.7" upper_limit="336.4"/>
                    <measurement group_id="O2" value="228.4" lower_limit="168.5" upper_limit="309.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="21.8" upper_limit="33.6"/>
                    <measurement group_id="O2" value="31.6" lower_limit="25.1" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.6" lower_limit="131.4" upper_limit="198.6"/>
                    <measurement group_id="O2" value="131.4" lower_limit="105.8" upper_limit="163.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 0 and Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/New Caledonia, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.6" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.3" upper_limit="12.1"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.0" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.6" upper_limit="7.8"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
        <description>The geometric mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
          <description>The geometric mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>cytokine-positive cells/million cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Doubles, B/Malaysia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.58" spread="348.81"/>
                    <measurement group_id="O2" value="451.35" spread="448.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, B/Malaysia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1555.92" spread="1060.11"/>
                    <measurement group_id="O2" value="736.15" spread="588.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, A/New Caledonia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.57" spread="348.20"/>
                    <measurement group_id="O2" value="370.36" spread="408.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, A/New Caledonia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872.71" spread="662.32"/>
                    <measurement group_id="O2" value="510.86" spread="604.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, A/Wisconsin, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.33" spread="155.75"/>
                    <measurement group_id="O2" value="50.79" spread="212.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.74" spread="412.68"/>
                    <measurement group_id="O2" value="72.43" spread="190.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, B/Malaysia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.07" spread="328.40"/>
                    <measurement group_id="O2" value="433.94" spread="406.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, B/Malaysia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1409.79" spread="983.81"/>
                    <measurement group_id="O2" value="694.68" spread="550.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/New Caledonia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.25" spread="337.18"/>
                    <measurement group_id="O2" value="354.60" spread="399.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/New Caledonia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="786.97" spread="598.31"/>
                    <measurement group_id="O2" value="475.96" spread="576.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/Wisconsin, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.53" spread="145.90"/>
                    <measurement group_id="O2" value="52.22" spread="208.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.23" spread="346.59"/>
                    <measurement group_id="O2" value="65.37" spread="168.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, B/Malaysia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.46" spread="297.90"/>
                    <measurement group_id="O2" value="244.30" spread="377.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, B/Malaysia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1081.98" spread="840.54"/>
                    <measurement group_id="O2" value="530.64" spread="451.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/New Caledonia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.76" spread="265.96"/>
                    <measurement group_id="O2" value="239.78" spread="285.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/New Caledonia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527.98" spread="522.30"/>
                    <measurement group_id="O2" value="407.10" spread="492.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/Wisconsin, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.45" spread="114.69"/>
                    <measurement group_id="O2" value="30.49" spread="83.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.99" spread="365.27"/>
                    <measurement group_id="O2" value="38.46" spread="126.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, B/Malaysia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.42" spread="318.77"/>
                    <measurement group_id="O2" value="382.48" spread="378.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, B/Malaysia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1297.82" spread="880.34"/>
                    <measurement group_id="O2" value="647.93" spread="508.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/New Caledonia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.57" spread="307.83"/>
                    <measurement group_id="O2" value="220.62" spread="301.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/New Caledonia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652.75" spread="539.89"/>
                    <measurement group_id="O2" value="300.71" spread="502.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/Wisconsin, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.74" spread="130.05"/>
                    <measurement group_id="O2" value="53.93" spread="127.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.97" spread="301.28"/>
                    <measurement group_id="O2" value="53.47" spread="148.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, B/Malaysia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.83" spread="298.11"/>
                    <measurement group_id="O2" value="331.52" spread="383.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, B/Malaysia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1098.28" spread="869.02"/>
                    <measurement group_id="O2" value="532.81" spread="420.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/New Caledonia, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.03" spread="276.48"/>
                    <measurement group_id="O2" value="261.91" spread="369.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/New Caledonia, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582.62" spread="506.95"/>
                    <measurement group_id="O2" value="317.96" spread="416.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/Wisconsin, Day 0 [N=73;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.29" spread="119.05"/>
                    <measurement group_id="O2" value="36.16" spread="190.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.99" spread="308.52"/>
                    <measurement group_id="O2" value="44.97" spread="157.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
        <description>The geometric mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
          <description>The geometric mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-g), at least IL2 and at least TNF alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine, for whom administration site of study vaccine was known, who did not receive a vaccine forbidden in the protocol and for whom immunogenicity data were available.</population>
          <units>cytokine-positive cells/million cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All doubles, B/Malaysia, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="83.49"/>
                    <measurement group_id="O2" value="4.17" spread="70.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All doubles, B/Malaysia, Day 21 [N=73;72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" spread="95.80"/>
                    <measurement group_id="O2" value="3.74" spread="120.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All doubles, A/New Caledonia, Day 0 [N=71;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="233.32"/>
                    <measurement group_id="O2" value="7.31" spread="112.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All doubles, A/New Caledonia, Day 21 [N=73;70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="191.24"/>
                    <measurement group_id="O2" value="4.40" spread="141.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All doubles, A/Wisconsin, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="82.82"/>
                    <measurement group_id="O2" value="6.79" spread="85.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All doubles, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="56.70"/>
                    <measurement group_id="O2" value="2.79" spread="70.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, B/Malaysia, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="34.98"/>
                    <measurement group_id="O2" value="2.11" spread="36.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, B/Malaysia, Day 21 [N=73;72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="45.91"/>
                    <measurement group_id="O2" value="1.98" spread="32.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/New Caledonia, Day 0 [N=71;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="113.11"/>
                    <measurement group_id="O2" value="5.34" spread="65.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/New Caledonia, Day 21 [N=73;70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="93.16"/>
                    <measurement group_id="O2" value="2.11" spread="51.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/Wisconsin, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="53.59"/>
                    <measurement group_id="O2" value="2.70" spread="44.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="39.28"/>
                    <measurement group_id="O2" value="2.11" spread="39.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, B/Malaysia, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="56.03"/>
                    <measurement group_id="O2" value="2.71" spread="56.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, B/Malaysia, Day 21 [N=73;72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="74.51"/>
                    <measurement group_id="O2" value="3.53" spread="118.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/New Caledonia, Day 0 [N=71;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="231.67"/>
                    <measurement group_id="O2" value="4.34" spread="97.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/New Caledonia, Day 21 [N=73;70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="174.85"/>
                    <measurement group_id="O2" value="3.98" spread="133.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/Wisconsin, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="73.55"/>
                    <measurement group_id="O2" value="4.40" spread="69.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="44.69"/>
                    <measurement group_id="O2" value="1.98" spread="36.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, B/Malaysia, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="92.44"/>
                    <measurement group_id="O2" value="2.12" spread="44.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, B/Malaysia, Day 21 [N=73;72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="60.32"/>
                    <measurement group_id="O2" value="2.44" spread="32.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/New Caledonia, Day 0 [N=71;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="131.52"/>
                    <measurement group_id="O2" value="4.43" spread="60.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/New Caledonia, Day 21 [N=73;70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="125.59"/>
                    <measurement group_id="O2" value="2.44" spread="62.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/Wisconsin, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="55.19"/>
                    <measurement group_id="O2" value="3.23" spread="61.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="45.28"/>
                    <measurement group_id="O2" value="2.55" spread="61.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, B/Malaysia, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" spread="83.63"/>
                    <measurement group_id="O2" value="4.29" spread="78.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, B/Malaysia, Day 21 [N=73;72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="91.95"/>
                    <measurement group_id="O2" value="3.90" spread="124.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/New Caledonia, Day 0 [N=71;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="218.59"/>
                    <measurement group_id="O2" value="6.05" spread="114.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/New Caledonia, Day 21 [N=73;70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" spread="171.91"/>
                    <measurement group_id="O2" value="5.50" spread="128.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/Wisconsin, Day 0 [N=72;69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="58.61"/>
                    <measurement group_id="O2" value="5.55" spread="92.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, A/Wisconsin, Day 21 [N=73;73]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="49.21"/>
                    <measurement group_id="O2" value="2.33" spread="70.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were considered to be related to vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were considered to be related to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 37.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented everyday activities. Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 30-day (Days 0-29) post vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented everyday activities. Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE considered by the investigator to have a causal relationship to study vaccination.</description>
        <time_frame>During the entire study period (from Day 0 to Day 29)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE considered by the investigator to have a causal relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on all subjects with the documented dose.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE(s): during the entire study (from Day 0 to Day 29); Solicited local and general symptoms: during the 7-day (Days 0-6) follow-up period after any vaccination; Unsolicited AE(s): during the 30-day (Days 0-29) follow-up period after any vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

